The Ontario Horse Racing Appeal Panel has denied the Canadian Hall of Fame driver’s request to put a stay on his 10-year ...

All three erythropoiesis-stimulating agents — the two recombinant erythropoietins (Epogen and Procrit) and the closely related protein darbepoetin alfa (Aranesp) — are FDA-approved ...

According to the results of a single-center, prospective, crossover study, darbepoetin alfa—a hyperglycosylated, and therefore longer-acting, derivative of epoetin—is a more effective ...

Purpose: The cost of darbepoetin alfa versus that of epoetin alfa in a hospital setting was studied. Methods: The study was an observational, retrospective review of the hospitalwide use of ...

When he worked for the California-based biotechnology company Amgen in the 1990s, Steve Elliott was instrumental in the development of darbepoetin alfa (Aranesp), a drug to treat anemia in people with ...

Darbepoetin alfa 10mcg/0.4mL, 25mcg/0.42mL, 40mcg/0.4mL, 60mcg/0.3mL, 100mcg/0.5mL, 150mcg/0.3mL, 200mcg/0.4mL, 300mcg/0.6mL, 500mcg/mL; per prefilled syringe; for IV ...

The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments ...

MK-2578, in phase 2 trials, was Merck's most advanced biosimilar—similar to Amgen's blockbuster Aranesp (darbepoetin alfa). “Other biosimilars counterparts will have to face [similarly] strict ...